- Home
- SBSI vs PRAX Comparison
SBSI vs PRAX Comparison
Compare SBSI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBSI
- PRAX
- Stock Information
- Founded
- SBSI 1960
- PRAX 2015
- Country
- SBSI United States
- PRAX United States
- Employees
- SBSI N/A
- PRAX N/A
- Industry
- SBSI Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- SBSI Finance
- PRAX Health Care
- Exchange
- SBSI Nasdaq
- PRAX Nasdaq
- Market Cap
- SBSI 920.2M
- PRAX 950.8M
- IPO Year
- SBSI N/A
- PRAX 2020
- Fundamental
- Price
- SBSI $31.31
- PRAX $48.78
- Analyst Decision
- SBSI Hold
- PRAX
- Analyst Count
- SBSI 3
- PRAX 0
- Target Price
- SBSI $35.00
- PRAX N/A
- AVG Volume (30 Days)
- SBSI 113.6K
- PRAX 541.9K
- Earning Date
- SBSI 07-25-2025
- PRAX 08-04-2025
- Dividend Yield
- SBSI 4.60%
- PRAX N/A
- EPS Growth
- SBSI 4.30
- PRAX N/A
- EPS
- SBSI 2.81
- PRAX N/A
- Revenue
- SBSI $254,956,000.00
- PRAX $7,765,000.00
- Revenue This Year
- SBSI $10.88
- PRAX N/A
- Revenue Next Year
- SBSI $5.60
- PRAX $3,567.38
- P/E Ratio
- SBSI $11.13
- PRAX N/A
- Revenue Growth
- SBSI 6.01
- PRAX 338.45
- 52 Week Low
- SBSI $25.85
- PRAX $26.70
- 52 Week High
- SBSI $38.00
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- SBSI 61.38
- PRAX 50.21
- Support Level
- SBSI $29.54
- PRAX $44.15
- Resistance Level
- SBSI $30.44
- PRAX $48.68
- Average True Range (ATR)
- SBSI 0.60
- PRAX 2.78
- MACD
- SBSI 0.14
- PRAX -0.34
- Stochastic Oscillator
- SBSI 100.00
- PRAX 49.73
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.